博拓生物(688767.SH):已推出具有性能競爭優勢的大麻唾液產品以及新型微量唾液毒品檢測板等多項新產品
格隆匯12月4日丨博拓生物(688767.SH)近期在接待機構投資者調研時表示,目前在美國,由於芬太尼被濫用嚴重,以芬太尼為主的阿片類藥物是美國人服藥過量死亡的主要原因之一。美國政府針對芬太尼等藥物濫用會公共發放單條試劑條,幫助服用藥物人羣檢測其使用的藥物中是否含有芬太尼,以減少其受到因服用阿片類藥物而受到的傷害。隨着美國大麻管控放鬆,其在美國多州已經合法化,使用大麻的人羣較多,美國每年對於招工、保險等多方面都會有較大需求,在毒駕方面也會進行大麻檢測,幫助警察判斷是否存在危險駕駛的隱患。公司目前已經推出具有性能競爭優勢的大麻唾液產品以及新型微量唾液毒品檢測板、新款單面和雙面唾液毒品檢測杯、甲苯㘔嗪粉末檢測試劑、卡芬太尼粉末檢測試劑等多項新產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.